MILESTONE PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 USD | +1.16% |
|
+2.94% | +4.79% |
Presenter SpeechAmit Hasija (Executives)Good afternoon. My name is Amit Hasija, and I'm the CF...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Calendar
2024-05-18
- Heart Rhythm Conference
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.75
USD
Average target price
10.25
USD
Spread / Average Target
+485.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.79% | 110M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| -11.90% | 22.41B | |
| +0.47% | 22.28B | |
| -5.57% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- MIST Stock
- News Milestone Pharmaceuticals Inc.
- Transcript : Milestone Pharmaceuticals Inc. - Special Call